h2 receptor

Mifentidine (DA 4577) is an orally available H2 receptor antagonist for the study of gastric emptying and experimental gastric and duodenal ulcers.

ICI 162,846 is an orally active and potent H2 receptor antagonist that inhibits gastric secretion and may be used in the study of duodenal ulcers.

BMY 25368 HCl is a competitive histamine H2 receptor antagonist that antagonizes gastric secretion stimulated by pentagastrin, ethacrynic choline, and food.

Oxmetidine (SKF 92994) is a novel H2 receptor antagonist that is cytotoxic. Oxmetidine inhibits transmembrane calcium flux in cardiac and vascular tissues and is used in the treatment of active duodenal ulcers.

Lavoltidine (Loxtidine) is a potent and selective H2 receptor antagonist, orally active and irreversible, that inhibits gastric acid secretion and is used in the treatment of gastroesophageal reflux disease.

Histamine Phosphate (Histamine acid phosphate) acts directly on the blood vessels to dilate arteries and capillaries mediated by both H 1- and H 2-receptors.

Histamine dihydrochloride (Ceplene) is dihydrochloride form of Histamine. Histamine is an organic nitrogen compound which is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.

Sufotidine (AH 25352X) is a highly selective competitive H2 receptor antagonist.

Impromidine is a highly potent and specific agonist of the histamine H2 receptor.

Dalcotidine (KU 1257) is a novel histamine H2 receptor antagonist with histamine H9 receptor antagonistic activity and antisecretory effects.The Ki value for binding to guinea pig cerebral cortex was 0.040 The KB value for antagonism of histamine-induced positive chronotropic responses in the right atrium of isolate guinea pigs was 0.041.Dalcotidine improves the quality of ulcer healing, and may contribute to a reduction in ulcer recurrence and relapse rates.

Oxmetidine FA is an orally available specific histamine H2 receptor antagonist with antiulcerogenic properties.

(±)-Tazifylline is a selective and long-acting antagonist of histamine H1 receptor. Tazifylline shows much lower affinity for H2 receptors, α- and β-adrenoceptors, 5-hydroxytryptamine and muscarinic receptor subtypes.

Impromidine hydrochloride is a very potent and specific histamine H2 receptor agonist for conducting cardiovascular studies.

LCB-2853 is a potent thromboxane A2 prostaglandin H2 (TXA2 PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.

CP-66948 is a potent histamine H2 receptor antagonist with inhibitory effect on gastric acid secretion and can be used to protect gastric and intestinal mucosa.

Donetidine is a histamine H2 receptor antagonist used to treat digestive disorders.

Pradigastat (LCQ-908) is an orally active, potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor for the treatment of constipation, which may be used in the study of obesity and diabetes.

Famotidine (MK-208) is a propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors on the basolateral membrane of parietal cells, famotidine reduces basal and nocturnal gastric acid secretion, thereby decreasing gastric volume, acidity, and the amount of gastric acid released in response to various stimuli.

Ranitidine (HSDB 3925) is a non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.

Cimetidine (SKF-92334) is a histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.

Alcaftadine (Lastacaft) is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

Ranitidine Hydrochloride (AH19065) is a member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.

Emedastine (LY188695) is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors.

Perphenazine (Trilafon) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.